Table 1 Clinical characteristics of 4... | American Society of Hematology

Table 1

Clinical characteristics of 4 patients with ticlopidine TMAs

Patient code	Age	Sex	Duration of ticlopidine (wk)	Creatinine (μmol/L)	Platelets pretherapy	Platelets posttherapy	LDH pretherapy (U/L)	LDH posttherapy (U/L)	Outcome	PEX sessions (N)	ADAMTS13 Activity (%)*
010	84	M	3	110	40	235	2555	NA	Death	8	<5
022	77	M	4	150	5	131	1084	214	Survival	10	<5
003	78	F	3.5	260	33	93	1005	1736	Death	3	<5
012	42	F	2.5	110	13	323	790	170	Survival	30	<5

Patient code	Age	Sex	Duration of ticlopidine (wk)	Creatinine (μmol/L)	Platelets pretherapy	Platelets posttherapy	LDH pretherapy (U/L)	LDH posttherapy (U/L)	Outcome	PEX sessions (N)	ADAMTS13 Activity (%)*
010	84	M	3	110	40	235	2555	NA	Death	8	<5
022	77	M	4	150	5	131	1084	214	Survival	10	<5
003	78	F	3.5	260	33	93	1005	1736	Death	3	<5
012	42	F	2.5	110	13	323	790	170	Survival	30	<5

Platelet values expressed as ×10³.

F, female; M, male; NA, not available; PEX, plasma exchange.

ADAMTS13 was assessed by both FRET-VWF assay (<5%) and immunoblot activity (<10%).